Read as letter
Read related AAAAI/ACAAI email to members
At the end of February 2018, we learned that we will be the only supplier of venom immunotherapy products in North America. In light of this situation, we have evaluated our production capabilities as they relate to our ability to indefinitely supply the entire North American market. We determined that a substantial investment in equipment, facility and staff is necessary to ensure a long-term, consistent supply of venom extracts. However, we are confident that the supply of venom extracts will not be interrupted or reduced as a result of our competitor’s withdrawal from the market.
We will continue to increase our production of venom extracts to minimize the chance of future shortages. We currently have sufficient supply, both on hand and in production, to meet the total U.S. demand. As a result, allergists should not hesitate to prescribe and maintain full dose venom immunotherapy at normal intervals, and resume treatment if treatment had been interrupted.
As we continue to build our venom supply, we will focus on the production of our 5- and 12-dose products. These presentations allow us to build inventory at a faster rate than other presentations, which will help ensure we have enough doses to meet patient needs in the U.S. As we move forward we will continue to assess our production capabilities and the mix of venom presentations we produce.
HollisterStier Allergy has, and will continue to be, your partner in subcutaneous immunotherapy. At the end of the day, our goal is to ensure patient safety through consistent supply of immunotherapy products. As always, we are grateful for your business and look forward to our continued partnership as your provider of allergy immunotherapy products.
